LENZ Therapeutics to Speak at 2024 Jefferies Global Healthcare Conference

LENZ Therapeutics, Inc. (Nasdaq: LENZ), a biopharmaceutical company in the late stages of clinical development, has announced that its President and CEO, Eef Schimmelpennink, will present at the Jefferies Global Healthcare Conference. This event will take place in New York City from June 5th to 6th, 2024. Schimmelpennink will present on June 6th at 2:00 p.m. ET. Alongside the presentation, company management will also engage in one-on-one meetings during the conference. The presentation will be available via a live audio webcast on the LENZ Therapeutics website, with a replay accessible for 30 days post-event.

LENZ Therapeutics is devoted to developing and bringing to market an innovative aceclidine-based eye drop aimed at improving near vision for individuals with presbyopia. This condition, which affects an estimated 1.8 billion people worldwide and 128 million in the United States, involves the gradual loss of the eye's ability to focus on close objects, typically occurring with age.

The company's leading product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the Phase 3 CLARITY study, which is a registration-enabling clinical trial designed to assess the efficacy and safety of this treatment for presbyopia. LENZ Therapeutics aims to offer a pharmaceutical solution that improves vision throughout the day for everyone affected by this common condition.

Headquartered in San Diego, California, LENZ Therapeutics continues to push forward with its mission to enhance the quality of life for people with presbyopia through innovative eye care solutions.